Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
S
Sanket S. Dhruva
(Section of Cardiology, Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco)
H
Hans-Georg Eichler
(Federation of Austrian Social Insurances, Vienna)
S
Steven K. Galson
(Boston Consulting Group, Los Angeles, CA)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 392, Issue 10
Published
March 06, 2025
Pages
939-941
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (3)
S
Sanket S. Dhruva
Section of Cardiology, Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco
H
Hans-Georg Eichler
Federation of Austrian Social Insurances, Vienna
S
Steven K. Galson
Boston Consulting Group, Los Angeles, CA
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582